Arbutus Biopharma Corporation (ABUS) News
Track canonical SquawkNews coverage tagged to ABUS, Arbutus Biopharma Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Arbutus Biopharma Corporation (ABUS) To Buy 46M Shares At $5.00 In $230M Tender
Arbutus announced preliminary results of its modified Dutch auction, expecting to repurchase 46.0M shares at $5.00 for $230M, ~23% of shares, with an estimated ~55% proration. About 153.3M shares are expected outstanding
EQUITY | Sep 30, 2026, 11:38 AM UTC
L
Arbutus Announces Preliminary Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
Arbutus Biopharma Corp NASDAQ:ABUS
NEWS | Sep 30, 2026, 11:33 AM UTC
M
Arbutus commences US$230M modified Dutch auction tender offer
Arbutus (ABUS) commences a US$230 million modified Dutch auction tender offer for its common shares at a price not greater than US$5.75 nor less than US$5.00 per share.
MNA | Aug 24, 2026, 11:30 AM UTC
M
Arbutus launches $230 million Dutch auction tender for common shares
Arbutus commences a US$230 million modified Dutch auction tender offer for its common shares at a price not greater than US$5.75 nor less than US$5.00 per share.
MNA | Aug 24, 2026, 11:30 AM UTC
H
Arbutus Biopharma ABUS offers expected to start Aug 24, 2026
Arbutus Biopharma Corp says a cash offer is expected to commence on or about August 24, 2026, with a purchase price of not less than US$5.00 and not more than US$5.75 per share.
MNA | Aug 21, 2026, 11:31 AM UTC
M
Arbutus (ABUS) plans up to $230m share repurchase via Dutch auction
Arbutus (ABUS) announces an intent to repurchase up to US$230 million of its common shares through a modified “Dutch Auction” tender offer.
MNA | Aug 21, 2026, 11:30 AM UTC
L
Arbutus Reports Q2 2026 Financial Results
Arbutus reports second quarter 2026 financial results and provides corporate update
EARNINGS | Aug 12, 2026, 11:30 AM UTC
L
ABUS +5% premarket after receiving $178M first payment from MRNA settlement
ABUS +5% premarket after receiving $178M first payment from MRNA settlement
EQUITY | Jul 16, 2026, 11:47 AM UTC
L
ABUS Arbutus initiates international patent infringement enforcement actions against Pfizer and Biontech, receives first payment from Modern
ABUS Arbutus initiates international patent infringement enforcement actions against Pfizer and Biontech, receives first payment from Moderna settlement agreement and announces intent to return capital to shareholders Ar
EQUITY | Jul 16, 2026, 11:31 AM UTC